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Abstract The pharmacokinetics (PK) of carrier-med-
iated agents (CMA) is dependent upon the carrier
system. As a result, CMA PK differs greatly from the PK
of small molecule (SM) drugs. Advantages of CMAs
over SMs include prolonged circulation time in plasma,
increased delivery to tumors, increased antitumor
response, and decreased toxicity. In theory, CMAs
provide greater tumor drug delivery than SMs due to
their prolonged plasma circulation time. We sought to
create a novel PK metric to evaluate the efficiency of
tumor and tissue delivery of CMAs and SMs. We
conducted a study evaluating the plasma, tumor, liver,
and spleen PK of CMAs and SMs in mice bearing
subcutaneous flank tumors using standard PK parame-
ters and a novel PK metric entitled relative distribution
over time (RDI-OT), which measures efficiency of
delivery. RDI-OT is defined as the ratio of tissue drug
concentration to plasma drug concentration at each time
point. The standard concentration versus time area
under the curve values (AUC) of CMAs were higher in
all tissues and plasma compared with SMs. However, 8
of 17 SMs had greater tumor RDI-OT AUC0–last values
than their CMA comparators and all SMs had greater
tumor RDI-OT AUC0–6 h values than their CMA
comparators. Our results indicate that in mice bearing
flank tumor xenografts, SMs distribute into tumor more
efficiently than CMAs. Further research in additional
tumor models that may more closely resemble tumors
seen in patients is needed to determine if our results are
consistent in different model systems.
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Introduction
There has been a great increase in the number of
carrier-mediated agents (CMA) being studied for
targeted drug delivery in the past 15 years (Ge et al.
2011). CMAs include liposomes, non-liposomal nano-
particles, and conjugated agents. Liposomes are
vesicles that consist of a phospholipid bilayer with
drug contained in the aqueous center or embedded in
the phospholipid bilayer. Liposomes may be either
conventional or stabilized with polyethylene glycol
(PEGylated), which greatly increases their circulation
time (Zamboni 2005). Non-liposomal nanoparticles
include solid lipid nanoparticles and polymeric nano-
particles. Solid lipid nanoparticles consist of a micro-
emulsion which has drug loaded in the lipid portion
(Ma et al. 2013). Polymeric nanoparticles consist of a
polymeric matrix that can be molded into different
shapes and sizes which has drug embedded within Chu
et al. 2013). Conjugated agents consist of a small
molecule (SM) drug which is linked to a polymer
(Walsh et al. 2012). The theoretical advantages of
CMAs include greater solubility, longer duration of
exposure, selective delivery of encapsulated drug to
the site of action, superior therapeutic index, and the
potential to overcome resistance associated with
anticancer agents (Drummond et al. 1999; Papahadj-
opoulos et al. 1991; Zamboni 2005, 2008). The
potential advantages of CMAs over traditional SM
drugs have led to interest in the development of carrier
mediated formulations of chemotherapeutic agents.
The pharmacokinetics (PK) of CMAs is dependent
upon the properties of the carrier and not the SM drug
until the drug is released from the carrier (Zamboni
2005, 2008). CMAs act as prodrugs and are not active
until the SM drug is released from the carrier. Once the
SM drug is released from the carrier, its PK is the same
as the non-carrier mediated formulation of that drug
(Zamboni 2008). Nomenclature has been created to
describe the different states of CMAs. The term
encapsulated or conjugated is used to describe the drug
still bound to or within the carrier. The term released
drug describes the drug after it has been released from
the carrier. The term sum total is used to describe the
sum of both encapsulated and released drug (Zamboni
2005). While SM drugs are typically metabolized by
the liver or eliminated by the kidney, it is thought that
CMAs are cleared mainly through the cells of the
mononuclear phagocyte system (MPS) (Caron et al.
2012; Laverman et al. 2001; Litzinger et al. 1994;
Zamboni 2005). The MPS comprises cells such as
macrophages and monocytes which phagocytose
pathogens and dead cells to remove them from the
body (Vonarbourg et al. 2006). Cells of the MPS take
up CMAs and transport them to the organs associated
with the MPS such as the liver and spleen, where they
are further degraded and removed from the body. Due
to the complex nature of CMA detailed PK and
biodistribution studies in animals and patients need to
be performed to evaluate their disposition (Zamboni
2008).
Tumor targeting by non-actively targeted CMAs
is believed to be a passive process via the enhanced
permeability and retention (EPR) effect (Alonso
2004; Matsumura and Maeda 1986). When SM
chemotherapeutic drugs are administered intrave-
nously, they quickly distribute to most tissues of the
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body, and rapidly diffuse out of these tissues. This
leads to low drug exposure in the tumor and
unnecessary exposure of healthy tissue to cytotoxic
agents. However, CMAs are not able to diffuse from
the peripheral circulation into normal tissues
because of their relatively large size, which means
that most of the dose remains in the central
compartment (the blood stream) (Duncan 1999;
Zamboni 2005). While CMAs are not able to enter
normal tissues, differences in tumor vascularity and
biology allow CMAs to enter and accumulate in
tumors. Tumor vasculature differs from the vascu-
lature of normal tissues in that it is abnormally
leaky, which allows CMAs to extravasate into the
extracellular fluid of tumors (Duncan 1999). In
addition to leaky vasculature, tumors also have
impaired lymphatic function, which decreases the
clearance of macromolecules from tumor (Matsum-
ura and Maeda 1986). In theory, this phenomenon is
known as the EPR effect and it allows CMA to
accumulate for extended durations in tumors
(Alonso 2004; Matsumura and Maeda 1986).
CMAs can be engineered to achieve much longer
plasma circulation times than SM (Drummond et al.
1999). It has been shown that steric stabilization of
CMAs reduces their rate of uptake by the MPS, though
the mechanism behind this phenomenon is unclear
(Zamboni 2005). Decreasing the rate of uptake of
CMAs by the MPS leads to a decreased plasma
clearance and thus a longer residence time in the
plasma after administration (Drummond et al. 1999).
CMAs that have been stabilized by PEGylation or
conjugation with other polymers can achieve plasma
half-lives of[40 h (Drummond et al. 1999). Theoret-
ically, the EPR effect, combined with the long plasma
circulation times seen with sterically stabilized agents,
would result in a more efficient delivery of CMAs to
tumors than is seen with SMs.
Standard PK parameters and metrics used for SMs
have been used to describe CMAs. However, these
standard PK parameters may not provide important
and detailed information that describes SMs and
CMAs, especially as related to efficiency of tumor
delivery. This study will evaluate the PK properties of
SMs and CMAs in mice with subcutaneous xenograft
and syngenetic tumors. The efficiency of CMAs and
SMs agents will be evaluated by a new PK metric, the
relative distribution over time (RDI-OT), which was
created for this analysis.
Materials and methods
Study design
A computerized literature search was conducted using
the MEDLINE database to find PK studies of CMAs
and SMs given intravenously in mice with xenograft
or synergistic subcutaneous tumors implanted on the
flank of mice. The bibliography of studies and
literature reviews identified in the MEDLINE search
were also used to identify additional studies. Inclusion
factors for the study were that the paper must report the
concentration versus time profile of the CMA and its
comparative SM in plasma and tumor, the mouse
model used, the tumor line, and dose of each agent
administered.
Data summary
Plasma and tumor concentration versus time profiles
were obtained from tables and concentration versus
time curves reported in the results sections of selected
articles. Liver and spleen concentration versus time
profiles were also obtained when available, as these
are organs of the MPS where the majority of the CMA
agents depot. Graph digitizing software (GetData
Graph Digitizer v. 2.24) was used to convert concen-
tration versus time curves to raw data.
PK analysis
The areas under the concentration versus time curves
(AUC) for plasma, tumor, liver, and spleen from 0 h to
time last and from 0 to 6 h were calculated by
noncompartmental analysis for each CMA and SM
agent using Phoenix WinNonlin version 6.2 (Phar-
sight, St. Louis, MO) The concentration versus time
profile was also used to calculate a new PK metric
entitled the relative distribution index over time (RDI-
OT). The RDI-OT is defined as the concentration of
drug in tumor or tissue divided by the concentration of
drug in the plasma at the corresponding time point.
Figure 1 illustrates an example RDI-OT calculation. A
theoretical tumor RDI-OT value at 6 h has been
calculated by dividing the tumor drug concentration at
6 h by the plasma drug concentration at 6 h. The RDI-
OT value for each PK time point can be calculated
using this method. The RDI-OT values were then
plotted against time to generate an RDI-OT versus
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time curve. For each agent, the RDI-OT values for
tumor, liver, and spleen were calculated at all PK time
points and then plotted against time. The area under
the RDI-OT versus time curves (RDI-OT AUC) from
0 h to time last and from 0 to 6 h were calculated by
noncompartmental analysis using Phoenix WinNonlin
version 6.2. RDI-OT AUC is different from the ratio of
tissue or tumor AUC to plasma AUC because there are
no tumor, tissue, or plasma AUC values used in the
calculation of RDI-OT. Rather, the ratio of drug
concentration in tumor or tissue to drug concentration
in plasma is calculated at each individual time point
then the values are plotted against time to create an
RDI-OT curve.
The following PK parameters were calculated for
all agents: standard plasma and tumor AUCs, ratio of
standard plasma AUC to standard tumor AUC, ratio of
(SM tumor AUC/plasma AUC) to (CMA tumor AUC/
plasma AUC), the tumor RDI-OT AUC from 0 h to
time last, the ratio of SM tumor RDI-OT AUC from
0 h to time last to its comparative CMA tumor RDI-
OT AUC from 0 h to time last, the tumor RDI-OT
AUC from 0 to 6 h, the ratio of SM tumor RDI-OT
AUC from 0 to 6 h to its comparative CMA tumor
RDI-OT AUC from 0 to 6 h, the liver RDI-OT AUC
from 0 h to time last, the liver RDI-OT AUC from 0 to
6 h, the spleen RDI-OT AUC from 0 h to time last,
and the spleen AUC RDI-OT from 0 to 6 h.
Statistical analysis
The mean, standard deviation, median, and range were
calculated for each PK parameter. The correlation of
RDI-OT values with tissue and plasma AUC ratios
was evaluated using Pearson’s correlation coefficient
(R). Wilcoxon Rank Sum tests were performed to
compare distributions of SM RDI-OT AUC to CMA
RDI-OT AUC. Differences in RDI-OT AUC distribu-




Our search identified 12 articles that met the inclusion













































RDI-OT[Tumor]/[Plasma] vs. time profile
[Drug]tumor at 6 hr/[Drug]plasma at 6 hr= RDI-OT at 6 hr
RDI-OT Formula
Fig. 1 Illustration of a theoretical relative distribution index-
over time (RDI-OT) calculation. Plot on the top left is a
theoretical tumor drug concentration versus time profile. Plot on
the top right is a theoretical plasma drug concentration versus
time profile. The 6 h RDI-OT value is calculated by dividing the
6 h tumor drug concentration by the 6 h plasma drug
concentration. The RDI-OT is calculated for each time point.
RDI-OT values can then be plotted against time (plot on the
bottom left) and the AUC of the RDI-OT curve can be calculated
as a measure of efficiency of drug delivery
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previously unpublished studies were included. In these
15 studies, PK data were available for 17 CMAs and
15 SMs (Chu et al. 2013; Desjardins et al. 2001; Farrell
2011; Feng et al. 2013; Forssen et al. 1992; Gabizon
et al. 1997; Konishi et al.2012; Ma et al. 2013; Mayer
et al. 1990; Sapra et al. 2008; Takahashi et al. 2010;
Valery et al. 1999; Walsh et al. 2012; Zamboni et al.
2004, 2007). Two of the studies compared two
separate CMA formulations to a single SM formula-
tion, which explains why there were data available for
2 more CMA than SM (Chu et al. 2013; Farrell 2011).
A summary of the mouse model used in each study, the
CMAs and their comparative SM agents, and the
tumor line for each study is presented in Table 1.
There were five non-liposomal nanoparticles, six
PEGylated liposomes, three non-PEGylated lipo-
somes, and three conjugate agents included in the
study. Additionally, we have included a summary of
the physiochemical properties (size, shape, zeta
potential, composition, and surface coating) of all
CMAs in Supplemental Table 1.
Standard PK results
The plasma concentration versus time profiles for all
agents are shown in Fig. 2. The agents have been
Table 1 Summary of CMA, SM, murine strain, and tumor models
CMA/comparative SM CMA type Mouse strain Tumor line Reference
SPI-077/cisplatin PEGylated liposome Female C57Bl/6 B16 murine melanoma Zamboni et al.
(2004)
S-CKD602/CKD-602 PEGylated liposome Female CB-17 SCID A375 human melanoma Zamboni et al.
(2007)








Female CB-17 SCID SKOV-3 human ovarian
carcinoma
Chu et al. (2013)





Female nu/nu KB nasopharyngeal
carcinoma
Farrell (2011)






Female BALB/c 4T1 Feng et al. (2013)
BTM-paclitaxel/paclitaxel Non-liposomal
nanoparticle
Female BALB/c 4T1 Ma et al. (2013)
NK012/SN-38 Conjugated agent Female BALB/c HT-29 colon carcinoma Takahashi et al.
(2010)
SP1049C/doxorubicin Conjugated agent Female C57Bl/6 s.c. 3LL-M27 Alakhov et al.
(1999)
ENZ-2208/SN-38 Conjugated agent Female BALB/c MX-1 breast carcinoma Sapra et al.
(2008)














OSI-211/lurtotecan Conventional liposome Female nu/nu KB (head/neck) Desjardins et al.
(2001)
All SM docetaxel is Taxotere. SM paclitaxel is Taxol. Liposomal daunorubicin is DaunoXome. Liposomal doxorubicin is
Myocet
PLD pegylated liposomal doxorubicin, SM small molecule, CMA carrier mediated agent
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classified by CMA subtype, with SMs being put in
their own class. Conjugated agents achieved the
greatest plasma concentrations, followed by PEGylat-
ed liposomes. Non-liposomal nanoparticle and con-
ventional liposomes had the lowest plasma
concentrations of the CMAs. SMs had the lowest
plasma concentrations of all agents. Predictably, SMs
were cleared quickly with most agents being unde-
tectable after 24 h. One exception to the fast clearance
of SMs was cisplatin where total cisplatin (protein
bound ? unbound drug) was detectable at 168 h after
administration. This can be explained by the fact that
cisplatin is highly and covalently bound to albumin
and therefore its prolonged exposure in the plasma is
indicative of albumin clearance (Oberoi et al. 2012).
The physiochemical properties of the CMAs had an
effect on the plasma PK of the CMAs. The major
factors affecting plasma PK were composition and
surface coating. In general, particles that were coated
with PEG achieved much higher plasma concentra-
tions and had much longer circulation times. In
addition, conjugated agents achieved higher plasma
concentrations and circulated longer than agents
composed of lipids or polymers that were not PEGy-
lated. No other physiochemical properties were asso-
ciated with the plasma PK of the agents evaluated.
The tumor concentration versus time profiles of all
agents included in the analysis are shown in Fig. 3. As
reported with the plasma concentration profiles, most
CMAs achieve higher tumor concentrations than SMs.
Fig. 2 Comparison of concentration versus time profiles in
plasma following the administration of CMAs and SMs. The
plasma concentration versus time curves for all agents identified
in the study. Curves with corresponding symbols indicate that
those agents are from the same study. Blue curves represent
SMs, green curves represent non-liposomal nanoparticles, black
curves represent PEGylated lipsomes, orange curves represent
non-PEGylated liposomes, and red curves represent conjugated
agents. (Color figure online)
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There is more variability and less systematic order
seen in CMA tumor disposition than is seen in plasma,
though the conjugated agents again achieve some of
the highest tumor exposures. Cisplatin and docetaxel
are two SMs that are detectable in tumor for an
extended period of time. Cisplatin’s extended expo-
sure in tumors can be explained by its covalent binding
to proteins in plasma, tumor, and tissues as described
above. Docetaxel’s extended duration of exposure is
likely due to its formulation characteristics. Docetaxel
(Taxotere) has poor aqueous solubility and thus a
surfactant, polysorbate 80, is used in the IV
formulation to improve solubility (Hennenfent and
Govindan 2006). This formulation leads to the
formation of micelles that encapsulate docetaxel,
which may give the drug CMA-like properties (van
Zuylen et al. 2001). Table 2 summarizes the standard
AUC data for both SMs and CMAs in plasma and
tumor. The mean CMA plasma AUC was 387-fold
greater than mean SM plasma AUC. Mean CMA
tumor AUC was 25-fold greater than mean SM tumor
AUC. The ratio of tumor AUC to plasma AUC is used
as a measure of the degree of tumor delivery. The ratio
of SM tumor AUC to plasma AUC divided by the ratio
Fig. 3 Comparison of concentration versus time profiles in
tumor following the administration of CMAs and SMs. The
tumor concentration versus time curves for all agents identified
in the study. Curves with corresponding symbols indicate that
those agents are from the same study. Blue curves represent
SMs, green curves represent non-liposomal nanoparticles, black
curves represent PEGylated lipsomes, orange curves represent
non-PEGylated liposomes, and red curves represent conjugated
agents. (Color figure online)
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of CMA tumor AUC to plasma AUC was used to
directly compare the degree of tumor delivery for each
formulation. A ratio value of greater than 1.0 indicates
that the SM has a greater degree of tumor delivery than
its comparative CMA. The mean ± SD ratio value for
SM to CMA was 40.1 ± 112.4 and 14 of the 17 values
Table 2 Standard pharmacokinetics parameters for CMA and SM agents







SPI-077 8,369,500.0 1,331,400.0 0.2 4.3
S CKD-602 201,929.0 13,194.0 0.1 19.6
XMT-1001 3,307,791.0 541,537.0 0.2 9.0
PRINT docetaxel 200 9 200 nm 138,359.5 396,104.1 2.9 13.5
PRINT docetaxel 80 9 320 nm 136,416.9 342,937.0 2.5 15.4
CS0201 4,590,300.0 1,644,300.0 0.4 15.3
Folate-CS0201 3,243,300.0 1,296,700.0 0.4 13.7
IHL-305 1,172,523.0 43,936.4 0.04 473.1
BTM-docetaxel 265,300.0 70,600.0 0.3 11.1
BTM-paclitaxel 13,718,752.0 3,600,767.8 0.3 7.8
NK012 5,821,004.0 13,336,462.9 2.3 0.8
SP1049C 10,518.8 49,921.5 4.8 0.9
ENZ-2208 90,889,572.2 35,400,531.0 0.4 0.7
PLD 4,225,761.4 564,647.8 0.1 58.9
Liposomal daunorubicin 2,096,021.1 2,439,618.8 1.2 22.4
Liposomal doxorubicin 96,627.6 109,800.0 1.1 7.7
OSI-211 446,407.6 83,275.8 0.2 6.8





0.4 (0.04–4.7) 11.1 (0.7–473.1)
SM
Cisplatin (SPI-077) 7,200.0 4,900.0 0.7
CKD-602 (S CKD-602) 9,117.0 11,661.0 1.3
CPT-11 (XMT-1001) 133,754.0 195,991.0 1.5
Docetaxel (PRINT docetaxel 200 9 200 nm/
80 9 320 nm)
5,809.6 224,481.1 38.6
Cisplatin (CS0201/folate-CS0201) 37,500.0 205,600.0 5.5
CPT-11 (IHL-305) 530.3 9,401.0 17.7
Docetaxel (BTM-docetaxel) 2,400.0 7,100.0 3.0
Paclitaxel (BTM-paclitaxel) 73,897.0 151,972.1 2.1
SN-38 (NK012) 1,276.4 2,265.6 1.8
Doxorubicin (SP1049C) 7,052.7 29,775.3 4.2
SN-38 (ENZ-2208) 2,843.9 796.2 0.3
Doxorubicin (PLD) 15,110.0 118,814.3 7.9
Daunorubicin (liposomal daunorubicin) 9,323.2 242,951.8 26.1
Doxorubicin (liposomal doxorubicin) 5,488.1 48,116.6 8.8
Lurtotecan (OSI-211) 4,598.3 5,852.3 1.3
Mean ± SD 21,060.0 ± 36,552.3 83,978.6 ± 94,516.9 8.0 ± 11.1
Median (Range) 7,052.7 (530.3–133,754.0) 29,775.3 (796.2–242,951.8) 3.0 (0.3–38.6)
All SM docetaxel is Taxotere. SM paclitaxel is Taxol. Liposomal daunorubicin is
DaunoXome. Liposomal doxorubicin is Myocet
PLD pegylated liposomal doxorubicin, SM small molecule, CMA carrier mediated agent, SD standard deviation, AUCplasma area under the plasma concentration
versus time curve, AUCtumor area under the tumor concentration versus time curve (AUCtumor/AUCplasma)SM ratio of SM tumor AUC to SM plasma AUC,
(AUCtumor/AUCplasma)CMA ratio of CMA tumor AUC to CMA plasma AUC
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were greater than 1 suggesting SMs have a greater
degree of tumor penetration compared with CMAs.
The CMAs’ physiochemical properties also had an
effect on their tumor PK. As was previously seen with
plasma PK, the major factor affecting tumor CMA PK
was PEGylation, with PEGylated agents achieving
higher tumor concentrations than CMA compared
with non-PEGylated agents. Particle composition
played less of a role in influencing the tumor CMA
PK compared with plasma PK. No other physiochem-
ical properties were seen to affect tumor PK.
RDI-OT PK results
The tumor to plasma RDI-OT versus time curves for
all agents included in the analysis are shown in Fig. 4.
SM tumor RDI-OT curves are higher than CMA RDI-
OT curves from 0 to 6 h, indicating that in the hours
directly after administration, SMs distribute more
efficiently to tumors than CMAs. The tumor to plasma
RDI-OT data for all agents is summarized in Table 3.
Truncated 0–6 h RDI-OT AUCs are provided to
account for the fact that SM drugs are cleared faster
Fig. 4 Tumor RDI-OT versus time curves following the
administration of CMAs and SMs. The tumor RDI-OT versus
time curves for all agents included in the study. Tumor RDI-OT
is defined as the concentration of drug in tumor divided by the
concentration of drug in plasma at each time point. Curves with
corresponding symbols indicate that those agents are from the
same study. Blue curves represent SMs, green curves represent
non-liposomal nanoparticles, black curves represent PEGylated
lipsomes, orange curves represent non-PEGylated liposomes,
and red curves represent conjugated agents. (Color figure online)
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SPI-077 131.3 0.02 0.02 98.7
S CKD-602 18.6 2.1 0.04 149.3
XMT-1001 6,488.0 0.03 0.1 76.1
PRINT docetaxel 200X200 nm 24,010.9 0.5 2.4 59.2
PRINT docetaxel 80X320 nm 7,152.7 1.6 2.5 55.8
CS0201 1,131.3 1.3 0.2 59.5
Folate-CS0201 2,860.5 0.5 0.2 63.6
IHL-305 3.0 1.5 0.1 63.8
BTM-docetaxel 109.9 0.2 0.3 26.7
BTM-paclitaxel 1,268.2 2.6 0.1 129.9
NK012 741,095.9 9.3 9 10-5 0.1 87.3
SP1049C 767.9 0.8 5.2 2.8
ENZ-2208 368.5 2.2 9 10-3 0.3 3.1
PLD 273.8 1.3 N/A N/A
Liposomal daunorubicin 414.7 13.4 0.8 45.4
Liposomal doxorubicin 791.9 0.1 1.0 12.5
OSI-211 31.3 2.0 0.5 45.5
Mean ± SD 46,289.3 ± 179,143.8 1.7 ± 3.1 0.87 ± 1.40b 61.2 ± 41.4
Median (Range) 767.9 (3.0–741,095.9) 0.9 (0.00009–13.4) 0.25 (0.02–5.2) 59.4 (2.8–149.3)
SM
Cisplatin (SPI-077) 2.3 2.3
CKD-602 (S CKD-602) 39.0 6.6
CPT-11 (XMT-1001) 219.4 11.1
Docetaxel (PRINT docetaxel
200 9 200 nm/80 9 320 nm)
11,057.7 141.9
Cisplatin (CS0201/folate-CS0201) 1,443.1 11.0
CPT-11 (IHL-305) 4.5 4.5
Docetaxel (BTM-docetaxel) 22.5 6.7
Paclitaxel (BTM-paclitaxel) 3,292.0 11.3
SN-38 (NK012) 68.9 9.3
Doxorubicin (SP1049C) 628.2 14.5
SN-38 (ENZ-2208) 0.8 0.8
Doxorubicin (PLD) 366.5 N/A
Daunorubicin (liposomal daunorubicin) 5,568.4 34.9
Doxorubicin (liposomal doxorubicin) 700.0 12.9
Lurtotecan (OSI-211) 61.6 24.0
Mean ± SD 1,565.0 ± 3,053.6 20.8 ± 36.0
Median (Range) 144.1 (0.8–11,057.7) 11.1 (0.8–141.9)
All SM docetaxel is Taxotere. SM paclitaxel is Taxol. Liposomal daunorubicin is DaunoXome. Liposomal doxorubicin is Myocet
PLD pegylated liposomal doxorubicin, SM small molecule, CMA carrier mediated agent, SD standard deviation, RDI-OTtumorAUC0–last area under the
tumor relative distribution index-over time versus time curve from 0 h to last pharmacokinetic time point, RDI-OTtumor AUC0–6 h area under the tumor
relative distribution index-over time versus time curve from 0 to 6 h
a Units: (ng*g-1/ng*mL-1)*h
b Different from SM (P \ 0.05)
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than CMAs and therefore cannot have RDI-OT values
at later time points. The ratio of SM RDI-OT
AUC0–last value to comparative CMA RDI-OT
AUC0-last value was calculated for all agents. In
addition, the ratio of SM RDI-OT AUC0–6 h value to
comparative CMA RDI-OT AUC0–6 h value was also
calculated for all the agents. These parameters were
used to directly compare the efficiency of tumor
delivery between SM and CMA. Ratio values greater
than 1.0 indicate that SMs have more efficient tumor
delivery than their comparative CMA. Eight of the 17
(48 %) SM RDI-OT AUC0–last to comparative CMA
RDI-OT AUC0–last ratios were greater than 1.0. In
addition, 16 of the 16 SM RDI-OT AUC0–6 h to
comparative CMA RDI-OT AUC0–6 h ratios were
greater than 1.0. These results indicate that the
majority of SMs have more efficient delivery to tumor
compared to their comparative CMA, especially in the
hours directly after administration.
RDI-OT AUC0–last and RDI-OT AUC0–6 h for both
liver and spleen are summarized in Table 4. Six of 14
SMs have a greater liver RDI-OT AUC0–last than their
comparative CMA, while all SMs have a greater liver
RDI-OT AUC0–6 h than their comparative CMA.
Three of 12 SMs have a greater spleen RDI-OT
AUC0–last than their comparative CMA, while all SMs
have a greater spleen RDI-OT AUC0–6 h than their
comparative CMA. The results of liver and spleen
RDI-OT are more variable than that of tumor.
However, when RDI-OT AUCs are measured to 6 h,
all SMs in both liver and spleen achieve greater RDI-
OT AUCs than their comparative CMA.
Comparison of standard and RDI-OT PK
parameters
The association between RDI-OT AUC and ratio of
tissue or tumor AUC to plasma AUC for both CMAs and
SMs is shown in Fig. 5. There is no association between
RDI-OT AUC and ratio of tissue AUC to plasma AUC
for either SMs or CMAs in any tissue, with the exception
for SM in tumor (R = 0.87). However, the association
of RDI-OT AUC and ratio of tumor AUC to plasma
AUC for SM appears to be driven by the presence of two
outliers, as when these two outliers are removed no
association is observed (R = -0.0436). The lack of
association between RDI-OT AUC and AUC ratio in
both tumor and tissues suggest that that RDI-OT is a
novel PK parameter that is independent from tumor or
tissue AUC to plasma AUC ratio and thus is measuring a
different PK principle.
Discussion
The evaluation of the PKs of CMAs relative to SMs
has been limited due to the lack of development of PK
metrics and parameters that evaluate the degree and
efficiency of distribution to tissues and especially
tumors. Thus, we developed a novel PK parameter
called RDI-OT that evaluates the efficiency of deliv-
ery of CMAs and SMs to tumors and tissues. CMAs
have much greater plasma exposure compared to SMs
due to their long residence time in the plasma, which is
easily seen when the plasma concentration versus time
curves and AUCs of CMAs are compared with those of
SMs. The tumor AUCs of CMAs are also higher than
the tumor AUCs of SMs, presumably due to the EPR
effect (Duncan 1999; Zamboni 2005, 2008). However,
using RDI-OT, we have shown that in mice with flank
subcutaneous human xenograft and flank synergistic
tumors, SMs distribute into tumor more efficiently
than CMAs. In addition, 14 of 17 (82 %) SMs have a
greater tumor AUC to plasma AUC ratio than their
comparative CMA. While SMs are cleared from
plasma much faster than CMAs the proportion of
tumor drug exposure relative to plasma drug exposure
is greater for SMs compared to CMAs. In addition,
every small SM tumor RDI-OT AUC0–6 h value is
greater than that of its comparative CMA. This
suggests that tumor distribution of CMAs is less
efficient than SMs. The reason for lower efficiency of
CMA tumor delivery compared to SMs is unclear.
Liver and spleen had more variable RDI-OT results
than tumor. Only a quarter of SMs managed to achieve
a greater RDI-OT AUC0–last than their comparative
CMA in spleen and only 6 of 14 (43 %) SMs achieved
a greater RDI-OT AUC0–last than their comparative
CMA in liver. However, this is to be expected as
CMAs have a much longer exposure than SMs and
therefore can have RDI-OT values calculated out to
much later time points. When RDI-OT AUC values
are truncated to 6 h, liver results start to fall in line
with the tumor results, with all SMs achieving a
greater liver RDI-OT AUC0–6 h than their comparative
CMA. Truncating spleen RDI-OT AUC values to 6 h
produces the same results, with all SMs achieving a
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SPI-077 392.9 0.1 1,117.7 0.1
S CKD-602 11.62 0.4 46.1 0.3
XMT-1001 26,188 1.0 14,915.0 0.4
PRINT docetaxel 200X200 11,917.6 3.0 112,966.7 21.9
PRINT docetaxel 80X320 526.5 1.6 2,292.0 9.8
CS0201 488 0.6 3,428.0 0.7
Folate-CS0201 5,707 1.4 4,130.0 0.8
IHL-305 4.5 0.3 9.3 0.4
BTM-docetaxel 906.9 13.3 303.7 6.3
BTM-paclitaxel 42,118.5 1.2 56,669.6 1.4
NK012 2,833,721.1 0.9 5,152,753.6 0.7
SP1049C 1,167.2 50.0 N/A N/A
ENZ-2208 N/A N/A N/A N/A
PLD 367.0 N/A N/A N/A
Liposomal daunorubicin N/A N/A N/A N/A
Liposomal doxorubicin N/A N/A N/A N/A
OSI-211 38.4 1.8 204.2 2.5







Cisplatin (SPI-077) 8.9 9.0 1.7 1.7
CKD-602 (S CKD-602) 96.0 40.0 22.1 10.6
CPT-11 (XMT-1001) 490.6 68.8 917.7 83.0
Docetaxel (PRINT docetaxel
200 9 200 nm/80 9 320 nm)
127.8 22.4 186.2 42.0
Cisplatin (CS0201/folate-CS0201) 2,743.0 17.0 647.0 2.1
CPT-11 (IHL-305) 14.4 28.4 27.7 34.5
Docetaxel (BTM-docetaxel) 83.3 39.0 535.7 201.5
Paclitaxel (BTM-paclitaxel) 2,240.0 42.4 969.8 9.3
SN-38 (NK012) 107.9 26.1 10.3 2.2
Doxorubicin (SP1049C) 1,534.7 72.5 N/A N/A
SN-38 (ENZ-2208) N/A N/A N/A N/A
Doxorubicin (PLD) 409.8 N/A N/A N/A
Daunorubicin (liposomal doxorubicin) N/A N/A N/A N/A
Doxorubicin (liposomal doxorubicin) N/A N/A N/A N/A
Lurtotecan (OSI-211) 271.0 85.4 230.6 100.4
Mean ± SD 677.3 ± 949.6 41 ± 24.6 354.9 ± 382.7 48.73 ± 64.1
Median (Range) 199.4 (8.9–2,743.0) 39 (9.0–85.4) 208.4 (1.7–969.8) 22.6 (1.7–201.5)
All SM docetaxel is Taxotere. SM paclitaxel is Taxol. Liposomal daunorubicin is DaunoXome. Liposomal doxorubicin is Myocet
PLD pegylated liposomal doxorubicin, SM small molecule, CMA carrier mediated agent, SD standard deviation, RDI-OTtumor AUC0–last area
under the tumor relative distribution index-over time versus time curve from 0 h to last pharmacokinetic time point, RDI-OTtumor AUC0–6 h
area under the tumor relative distribution index-over time versus time curve from 0 to 6 h
a Units: (ng*g-1/ng*mL-1)*h
b Different from SM (P \ 0.05)
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greater spleen RDI-OT AUC0–6 h than their compar-
ative CMA.
RDI-OT is a new PK metric to evaluate the
efficiency of drug delivery from plasma to tumor and
tissues. The purpose of RDI-OT is not to bypass
circulation ability; rather it is to evaluate the ability of
CMAs and SMs to penetrate into tumor from circula-
tion. By evaluating the relationship between plasma
drug concentration and tumor or tissue drug concen-
tration, we attempted to demonstrate that high plasma
drug concentrations do not necessarily result in con-
tinually rising tumor and tissue concentrations. Log-
ically, it would be expected that while plasma
concentrations are high, tumor and tissue drug con-
centrations would continue to increase. Using RDI-
OT, we have shown that this is not necessarily the case.
A high plasma concentration combined with low
tumor/tissue concentration is indicative of inefficient
tissue/tumor delivery and results in a low RDI-OT
value which corresponds with low efficiency. RDI-OT
is different from the ratio of tissue or tumor AUC to
plasma AUC because there are no tumor, tissue, or
plasma AUC values used in the calculation of RDI-OT.
Rather, the ratio of drug concentration in tumor or
tissue to drug concentration in plasma is calculated at
each individual time point. Once these calculations are
made, they can be plotted against time and the AUC
can be calculated creating the RDI-OT AUC. Further-
more, when RDI-OT AUCs were compared to ratios of
tissue or tumor AUC to plasma AUC, there was no
Fig. 5 Association between RDI-OT AUC in tumor and
tissues, and ratio of tumor AUC or tissue AUC to plasma
AUC for CMA and SM. a Association between SM RDI-
OTtumor AUC0–last [(ng*g
-1/ng*mL-1)*h] and SM tumor AUC
to plasma AUC ratio. Two outliers have been removed.
b Association between CMA RDI-OTtumor AUC0–last
[(ng*g-1/ng*mL-1)*h] and CMA tumor AUC to plasma AUC
ratio. c Association between RDI-OTliver AUC0–last [(ng*g
-1/
ng*mL-1)*h] and liver AUC to plasma AUC ratio. SMs (red)
and CMAs (blue) have been compared separately. d Association
between RDI-OTspleen AUC0–last [(ng*g
-1/ng*mL-1)*h] and
spleen AUC to plasma AUC ratio. SMs (red) and CMAs (blue)
have been compared separately. *Two outliers have been
removed. R = 0.8653 with outliers included. (Color figure
online)
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association between these values for either CMAs or
SMs in all the tissues observed. In addition to the
mathematical differences between RDI-OT and ratio
of tumor AUC to plasma AUC, RDI-OT provides
several additional unique results that AUC calculations
do not. First, RDI-OT can assess the efficiency of the
ability of SMs and CMAs to enter tissues and tumor
from plasma, whereas AUC ratio is only a relative
measure of the total drug exposure between plasma and
tumor or tissues. Second, RDI-OT values are calcu-
lated for each time point and thus it is possible to
evaluate the efficiency of a SM or CMA drug at single
time point and at various time points, while AUC ratio
can only measure the total exposure over the total
period of time. Thus, RDI-OT is a novel PK metric that
can be used to evaluate the efficiency of delivery of
CMAs and SMs to tumors and tissues.
While RDI-OT is a novel PK metric, it has not yet
been correlated to pharmacodynamics (PD) effects.
Future studies should be performed to determine what
effect RDI-OT has on PD outcomes. It would be useful
to see how RDI-OT values correlates to tumor
regression as well as overall survival. These studies
will be important to determine how RDI-OT relates to
the efficacy of both CMA and SM agents.
The results of this study do give us novel insights
into the plasma, tissue, and especially tumor PK
disposition of CMAs; however, there are some limi-
tations. All of the tumor models studied in this analysis
were subcutaneous flank xenografts. Recent studies
have shown that the PK of carboplatin in genetically
engineered mouse models (GEMMs) of melanoma
more closely resembles the tumor disposition of
carboplatin seen in patient with cutaneous tumors
when compared to other transplanted melanoma tumor
models (Combest et al. 2012). The combination of the
results from the study by Combest et al. (2012), and
our current study suggest that flank tumor models may
not be optimal to evaluate the tumor delivery and
efficacy of CMAs. However, the comparison of the
tumor delivery of CMAs and SMs in several types of
tumors models and in patients with solid tumors needs
to be performed to confirm these results. In addition,
our current study may need to be repeated in models
which more closely resemble tumors seen in patients,
such as orthotopic or GEMMs.
An additional limitation of this study was that the
total (encapsulated ? released) concentration of
CMAs was compared to the concentration of their
comparator SMs. Ideally, we would have compared the
concentration of encapsulated and released drug from
CMAs to the concentrations of their comparator SMs.
To more thoroughly evaluate the plasma and tumor
disposition of CMAs, it would be best to evaluate
encapsulated and released drug in plasma and tumor.
However, most of these studies were performed before
methods were available to measure encapsulated and
released drug in plasma. In addition, it is still very
difficult to measure encapsulated and released drug in
tumor and other tissues, as most methods for measuring
drug concentrations in tissue cause the encapsulated
drug to be released during the process. However, this
limitation of our study does highlight the need to
develop novel methods to measure encapsulated and
released drug in plasma, tumor, and tissues for all
CMAs.
Lastly, the results from this study could be inter-
preted differently depending on one’s views concern-
ing the mechanism of CMA drug delivery.
Contradictory to current theories for CMA tumor
delivery, which suggest that CMAs preferentially
accumulate in the tumor prior to releasing their
contents; it is possible that CMAs do not accumulate
in the tumor at all. Instead, tumor drug exposure could
be related only to the drug that is released from the
carrier into the blood and is then distributed to the
tumor as free SM drug. If this alternative theory is the
primary mechanism of tumor drug delivery, it is
possible that the RDI-OT values of CMAs are lower
than those of SMs, not because they distribute into the
tissues less efficiently than SMs, but rather because
CMAs release their contents from the carrier into the
blood stream at a very low rate. This potential
alternative theory also highlights the need to develop
methods to evaluate encapsulated and released drug in
blood, plasma, tumor, and tissues.
Conclusion
We have developed a new PK metric, RDI-OT, for the
evaluation of the efficiency of tumor and tissue drug
delivery of SMs and CMA drugs. Using this metric, we
have demonstrated that the efficiency of CMA tumor
delivery is lower than that of SM drugs in mice bearing
subcutaneous flank synergistic and xenograft tumors.
Additional studies are needed to evaluate if these
results are reproducible in additional tumor models. In
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addition, new methods, technologies, and model
systems are needed to improve the efficiency by which
CMAs are delivered to and penetrate into tumors.
Conflict of interest Research reported in this publication was
supported by the National Cancer Institute of the National
Institutes of Health under Award Number U54CA151652. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes
of Health.
References
Alakhov V, Klinski E, Li S, Pietrzynski G, Venne A, Batrakova
E et al (1999) Block copolymer-based formulation of
doxorubicin. From cell screen to clinical trials. Colloids
Surf B 16:113–134
Alonso MJ (2004) Nanomedicines for overcoming biological
barriers. Biomed Pharmacother 58:168–172
Caron WP, Song G, Kumar P, Rawal S, Zamboni WC (2012)
Interpatient pharmacokinetic and pharmacodynamic vari-
ability of carrier-mediated anticancer agents. Clin Phar-
macol Ther 91:802–812
Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM et al (2013)
Plasma, tumor and tissue pharmacokinetics of docetaxel
delivered via nanoparticles of different sizes and shapes in
mice bearing SKOV-3 human ovarian carcinoma xeno-
graft. Nanomedicine 9:686–693
Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK et al
(2012) Genetically engineered cancer models, but not xe-
nografts, faithfully predict anticancer drug exposure in
melanoma tumors. Oncologist 17:1303–1316
Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, Leray
JD, Brown EN et al (2001) Biodistribution of NX211,
liposomal lurtotecan, in tumor-bearing mice. Anticancer
Drugs 12:235–245
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjo-
poulos D (1999) Optimizing liposomes for delivery of
chemotherapeutic agents to solid tumors. Pharmacol Rev
51:691–743
Duncan R (1999) Polymer conjugates for tumour targeting and
intracytoplasmic delivery. The EPR effect as a common
gateway? Pharm Sci Technol Today 2:441–449
Farrell NP (2011) Platinum formulations as anticancer drugs
clinical and pre-clinical studies. Curr Top Med Chem
11:2623–2631
Feng L, Benhabbour SR, Mumper RJ (2013) Oil-filled lipid
nanoparticles containing 20-(2-bromohexadecanoyl)-
docetaxel for the treatment of breast cancer. Adv Healthc
Mater 2:1451–1457
Forssen EA, Coulter DM, Proffitt RT (1992) Selective in vivo
localization of daunorubicin small unilamellar vesicles in
solid tumors. Cancer Res 52:3255–3261
Gabizon Goren D, Horowitz T, Tzemach A, Losos A, Siegal T
et al (1997) Long-circulating liposomes for drug delivery
in cancer therapy: a review of biodistribution studies in
tumor-bearing animals. Adv Drug Deliv Rev 24:337–344
Ge Y, Tiwari A, Li S (2011) Nanomedicine—bridging the gap
between nanotechnology and medicine. Adv Mat Lett 2:1–2
Hennenfent KL, Govindan R (2006) Novel formulations of
taxanes: a review. Old wine in a new bottle? Ann Oncol
17:735–749
Konishi H, Takagi A, Kurita A, Kaneda N, Matsuzaki T (2012)
PEGylated liposome IHL-305 markedly improved the
survival of ovarian cancer peritoneal metastasis in mouse.
BMC Cancer 12:462
Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ,
van Rooijen N, Corstens FH, Storm G (2001) Factors
affecting the accelerated blood clearance of polyethylene
glycol-liposomes upon repeated injection. J Pharmacol
Exp Ther 298:607–612
Litzinger DC, Buiting AM, van Rooijen N, Huang L (1994)
Effect of liposome size on the circulation time and intra-
organ distribution of amphipathic poly(ethylene glycol)-
containing liposomes. Biochim Biophys Acta 1190:99–107
Ma P, Rahima Benhabbour S, Feng L, Mumper RJ (2013) 20-
Behenoyl-paclitaxel conjugate containing lipid nanoparti-
cles for the treatment of metastatic breast cancer. Cancer
Lett 334:253–262
Matsumura Y, Maeda H (1986) A new concept for macromo-
lecular therapeutics in cancer chemotherapy: mechanism
of tumoritropic accumulation of proteins and the antitumor
agent smancs. Cancer Res 46:6387–6392
Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT (1990)
Comparison of free and liposome encapsulated doxorubicin
tumor drug uptake and antitumor efficacy in the SC115
murine mammary tumor. Cancer Lett 53:183–190
Oberoi HS, Nukolova NV, Laquer FC, Poluektova LY, Huang J
et al (2012) Cisplatin-loaded core cross-linked micelles:
comparative pharmacokinetics, antitumor activity, and
toxicity in mice. Int J Nanomedicine 7:2557–2571
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay
K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann
C et al (1991) Sterically stabilized liposomes: improve-
ments in pharmacokinetics and antitumor therapeutic
efficacy. Proc Natl Acad Sci USA 88:11460–11464
Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C et al
(2008) Novel delivery of SN38 markedly inhibits tumor
growth in xenografts, including a camptothecin-11-
refractory model. Clin Cancer Res 14:1888–1896
Takahashi A, Ohkohchi N, Yasunaga M, Kuroda J, Koga Y,
Kenmotsu H et al (2010) Detailed distribution of NK012,
an SN-38-incorporating micelle, in the liver and its potent
antitumor effects in mice bearing liver metastases. Clin
Cancer Res 16:4822–4831
van Zuylen L, Verweij J, Sparreboom A (2001) Role of for-
mulation vehicles in taxane pharmacology. Invest New
Drugs 19:125–141
Vonarbourg A, Passirani C, Saulnier P, Benoit JP (2006)
Parameters influencing the stealthiness of colloidal drug
delivery systems. Biomaterials 27:4356–4373
Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB et al (2012)
Pharmacokinetics and antitumor efficacy of XMT-1001, a
novel, polymeric topoisomerase I inhibitor, in mice bearing
HT-29 human colon carcinoma xenografts. Clin Cancer
Res 18:2591–2602
Zamboni WC (2005) Liposomal, nanoparticle, and conjugated for-
mulations of anticancer agents. Clin Cancer Res 11:8230–8234
J Nanopart Res (2014) 16:2662 Page 15 of 16 2662
123
Zamboni WC (2008) Concept and clinical evaluation of carrier-
mediated anticancer agents. Oncologist 13:248–260
Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski
EG et al (2004) Systemic and tumor disposition of platinum
after administration of cisplatin or STEALTH liposomal-
cisplatin formulations (SPI-077 and SPI-077 B103) in a
preclinical tumor model of melanoma. Cancer Chemother
Pharmacol 53:329–336
Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA
et al (2007) Plasma, tumor, and tissue disposition of
STEALTH liposomal CKD-602 (S-CKD602) and nonlip-
osomal CKD-602 in mice bearing A375 human melanoma
xenografts. Clin Cancer Res 13:7217–7223
2662 Page 16 of 16 J Nanopart Res (2014) 16:2662
123
